Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1Burkitt Lymphoma 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 40Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Irinotecan 22Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14palbociclib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × CX 5461 × 1 year × Clear all
NCT07137416 2026-05-28

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
36 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06606990 2026-05-13

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

National Cancer Institute (NCI)

Phase 1 Recruiting
40 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡